@article{CCO20320,
author = {Bixia Tang and Xinan Sheng and Yan Kong and Zhihong Chi and Lu Si and Chuanliang Cui and Xieqiao Yan and Lili Mao and Bin Lian and Siming Li and Xuan Wang and Jie Dai and Xue Bai and Li Zhou and Jun Guo},
title = {Palbociclib for treatment of metastatic melanoma with copy number variations of CDK4 pathway: case report},
journal = {Chinese Clinical Oncology},
volume = {7},
number = {6},
year = {2018},
keywords = {},
abstract = {The mortality associated with unresectable or metastatic melanoma remains high despite of the emergence of new anti-tumor agents. In this case report, we present two metastatic melanoma patients with copy number variations (CNVs) of cyclin dependent kinase 4 (CDK4) pathway-related genes, who had failed in previous chemotherapy or immunotherapy, were treated with CDK4/6 inhibitor palbociclib and achieved tumor control for over 6 months. The copy number of CDK4, CCND1 and P16INK4a of one patient was 3.6, 3, 2 copies, and for the other patient, the copy number was 3, 2, 1 respectively. It indicates that CDK4 may be a potential target for melanoma.},
issn = {2304-3873}, url = {https://cco.amegroups.org/article/view/20320}
}